CalciMedica is trading at $0.78 (+5.04%) after the FDA aligned with the company on its Phase 2b Auxora trial design for acute pancreatitis.
- The trial endpoint is focused on new-onset severe respiratory failure, a move investors view as a significant de-risking step for the company's lead program.
- Broader market strength is providing additional tailwinds for the stock, with the Nasdaq climbing more than 2% during today's session.